Apexian Pharmaceuticals, Inc.
20 S. Meridian Street
Tel: 844-463-3330 ext. 114
About Apexian Pharmaceuticals, Inc.
Apexian Pharmaceuticals is a privately held clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. Established based upon the research of our founder and CSO, Mark Kelley, Ph.D., Apexian is advancing a lead drug candidate, APX3330, ready to move into clinical studies. Apexian will initially target late stage cancers refractory to existing treatments in a multi-center phase 1 clinical study. Several additional drug candidates are in pre-clinical development that came from an extensive structure activity relationship (SAR) to build a broad intellectual property portfolio in this target area. In addition to treating cancers directly, these molecules impact other important biological function and those are being assessed through collaborations with global researchers.
8 articles with Apexian Pharmaceuticals, Inc.
Apexian Pharmaceuticals, Inc. announced that it will report clinical data from its clinical study, APX-CLN-0011: A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors in a poster being presented on June 1 at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia
An obscure sliver of RNA with a grim-sounding name is unexpectedly taking center stage as a linchpin in transforming pre-leukemic cells into full-blown leukemia. Apexian Pharmaceuticals’ latest studies in collaboration with Indiana University’s Simon Cancer Center investigator Dr. Reuben Kapur show promise for halting that transformation.
Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia in Preclinical Models
Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia.
Apexian Pharmaceuticals Presents Data on Their Lead Drug for Anti-Chemotherapy-Induced Peripheral Neuropathy (CIPN), APX3330, at ASCO Palliative Care and Symptom Management Meeting
Chemotherapy causes chemotherapy-induced peripheral neuropathy (CIPN) in a significant number of patients, yet the pharmaceutical landscape is completely devoid of treatments to prevent CIPN.
Research focuses on Chemotherapy-Induced Peripheral Neuropathy
The study involves APX3330, a first in class orally administered inhibitor of APE1/Ref 1, a dual-function protein that plays a critical role in promoting and maintaining a broad variety of cancers.
This financing follows previous investments as well as numerous grants and awards by the company since its founding.